Skip to main content

Table 1 Summary of TCD 50 values and enhancement ratios (ER) for different treatments

From: BAY 87–2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts

Experimental arm TCD50[95% CI] (Gy) (p-value vs. control) ER
1) RT 122.7 [108;149] - -
2) BAY-87-2243 + RT 99.7 [88;117] (0.037) 1.23
3) BAY-87-2243 + RT/BAY-87-2243 114.3 [103;132] (0.4) 1.07
4) RCT 99.5 [83;124] - -
5) RCT/BAY-87-2243 107.2 [97;123] (0.5) 0.93
6) BAY-87-2243 + RCT/BAY-87-2243 113.6 [97; 145] (0.3) 0.88
  1. P-value <0.05 indicates significant differences between experimental treatment and respective control (RT or RCT).